Clinical Research Directory
Browse clinical research sites, groups, and studies.
3 clinical studies listed.
Filters:
Tundra lists 3 Mesothelin-positive Advanced Malignant Solid Tumors clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT06756035
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibody targeting Mesothelin, in subjects with advanced solid tumors associated with Mesothelin expression.
Gender: All
Ages: 18 Years - Any
Updated: 2025-07-31
7 states
NCT07010523
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of Anti-Mesothelin CAR-T cell injection in patients with Mesothelin-positive advanced malignant solid tumors.
Gender: All
Ages: 18 Years - 75 Years
Updated: 2025-06-08
NCT05783089
MSLN-targeted CAR-T Cells in Solid Tumors.
This study aims to explore the safety, tolerability and preliminary efficacy of Anti-Mesothelin CAR-T cells in subjects with Mesothelin-positive advanced malignant solid tumors.
Gender: All
Ages: 18 Years - Any
Updated: 2023-03-24